Though biologics are generally used in patients that fail to respond to previous therapies, the study reveals that early use of anti-TNF- α therapy in children diagnosed with moderate to severe Crohn’s disease is more effective at achieving remission than the current standard of treatment.
At one year, 85 percent of the patients receiving anti-TNF- α therapy achieved corticosteroid-free clinical remission.
More Articles on Gastroenterology:
10 Statistics on GI/Endoscopy Revenue Per Case Across the US
2014 CPT Code Update: GI/Endoscopy
FDA Regulation: 10 Elements of a New Drug Application for FMT
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
